Medicines for Addiction
Adial is a clinical-stage biopharmaceutical company focused on the treatment and prevention of addictions and other unmet medical needs.
RECENT NEWS
Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
March 24, 2026
H.R. 7091 Supports Development of Investigational Treatments for Alcohol Use Disorder and Aligns with Evolving Federal Recovery Standards GLEN ALLEN, Va., March 24, 2026 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders, today commended members of […]
HEAR FROM OUR EXPERTS
Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar.
Key Opinion Leader Webinar
Managing Through Mixed Trial Results And An Economic Downturn
Ben Comer
Chief Editor, Life Science Leader
November 1, 2022
What would Jack Welch do? Cary Claiborne knows the answer from nearly 15 years working at GE and GE Capital, during a time that overlapped closely with Welch’s tenure as CEO. In August, Claiborne himself became CEO of Adial Pharma, a Charlottesville, VA-based biopharmaceutical company with a novel approach to treating alcohol use disorder (AUD). Claiborne faces several distinct challenges: mixed topline results from a Phase 3 trial of lead candidate AD04, the potential need to fund and conduct another trial prior to seeking regulatory approval, and managing the company through a difficult economic downturn. Lessons learned during formative work experiences at GE, the first place Claiborne worked after graduating from Rutgers University in 1982, have followed him through executive-level financial roles in industries including telecoms, retail, energy, renewable fuels, and biopharmaceuticals.
Spotlight Series
Stay updated with insights from Adial’s executives on the latest company news and key developments in addiction research.
View All Spotlight Series
Damp January: Rethinking How Progress Is Defined in Alcohol Use Disorder
01/28/2026
Moving beyond all-or-nothing: defining progress through fewer risks, not perfection.
read more →AD04
Our lead investigational drug candidate, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated for the potential treatment of AUD in patients with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test.
Learn More